All In Biotech

Drug Trial Radar · NCT05126719

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

An Open-Label, Multi-Center Phase II Clinical Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 238 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

238

Planned (sponsor's estimate)

Start

Apr 6, 2023

Primary completion

Dec 30, 2024

Study completion Dec 30, 2026

Sponsor

Lead sponsor
Lepu Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in patients with recurrent metastatic nasopharyngeal carcinoma.

Conditions

  • Recurrent or Metastatic Nasopharyngeal Carcinoma

Interventions

  • MRG003Drug

    Administered intravenously

  • Capecitabine tabletsDrug

    Administered peros

  • Docetaxel injectionDrug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) by Independent Review Committee (IRC)Time frame: Baseline to disease progression, intolerable drug-related toxicities, withdrawal of consent, or study discontinuation for any reasons (up to 24 months)

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, China

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Maoming People's Hospital

    Maoming, Guangdong, China

  • Cancer Hospital of Shantou University Medical College

    Shantou, Guangdong, China

  • Yue Bei People's Hospital

    Shaoguan, Guangdong, China

  • Zhongshan City People's Hospital

    Zhongshan, Guangdong, China

  • Guigang City People's Hospital

    Guigang, Guangxi, China

  • Guangxi Medical University Affiliated Tumor Hospital

    Nanning, Guangxi, China

  • People's Hospital of Guangxi Zhuang Autonomous Region

    Nanning, Guangxi, China

  • The Affiliated Cancer Hospital of Guizhou Medical University

    Guiyang, Guizhou, China

  • Hainan General Hospital

    Haikou, Hainan, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • First Affiliated Hospital of Gannan Medical University

    Ganzhou, Jiangxi, China

  • Ganzhou Cancer Hospital

    Ganzhou, Jiangxi, China

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, China

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China

  • Yibin Second People's Hospital

    Yibin, Sichuan, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.